Evidence map›Paper›PMID 28763460›Full record

ArticlePloS one2017

Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells.

Dahai Yu, Lin Lv, Li Fang, Bo Zhang, Junnan Wang, Ge Zhan, Lei Zhao, Xin Zhao, Baoxin Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Quercetin is a foe in the heart by targeting the hERG potassium channel.Iranian journal of basic medical sciences · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dahai YuDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Lin LvDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Li FangDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Bo ZhangDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Junnan WangDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Ge ZhanDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Lei ZhaoDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Xin ZhaoDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
Baoxin LiDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.ORCID http://orcid.org/0000-0002-1680-3970
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human ether-a-go-go-related gene (hERG) potassium channel conducts rapid delayed rectifier potassium currents (IKr) and contributes to phase III cardiac action potential repolarization. Drugs inhibit hERG channels by binding to aromatic residues in hERG helixes. Berberine (BBR) has multiple actions, and its hydrogenated derivative dihydroberberine (DHB) is a potential candidate for developing new drugs. Previous studies have demonstrated that BBR blocks hERG channels and prolongs action potential duration (APD). Our present study aimed to investigate the effects and mechanism of DHB on hERG channels. Protein expression and the hERG current were analyzed using western blotting and patch-clamp, respectively. DHB inhibited the hERG current concentration-dependently after instantaneous perfusion, accelerated channel inactivation by directly binding tyrosine (Tyr652) and phenylalanine (Phe656), and decreased mature (155-kDa) and simultaneously increased immature (135-kDa) hERG expression, respectively. This suggests disruption of forward trafficking of hERG channels. Besides, DHB remarkably reduced heat shock protein 90 (Hsp90) expression and its interaction with hERG, indicating that DHB disrupted hERG trafficking by impairing channel folding. Meanwhie, DHB enhanced the expression of cleaved activating transcription factor-6 (ATF-6), a biomarker of unfolded protein response (UPR). Expression of calnexin and calreticulin, chaperones activated by ATF-6 to facilitate channel folding, were also increased, which indicating UPR activation. Additionally, the degradation rate of mature 155-kDa hERG increased following DHB exposure. In conclusion, we demonstrated that DHB acutely blocked hERG channels by binding the aromatic Tyr652 and Phe656. DHB may decrease hERG plasma membrane expression through two pathways involving disruption of forward trafficking of immature hERG channels and enhanced degradation of mature hERG channels. Furthermore, forward trafficking was disrupted by impaired channel folding associated with altered interactions between hERG proteins and chaperones. Finally, trafficking inhibition activated UPR, and mature hERG channel degradation was increased by DHB.

Indexed as

Action PotentialsActivating Transcription Factor 6BerberineCalnexinCalreticulinDrug DesignEther-A-Go-Go Potassium ChannelsGene Expression RegulationHEK293 CellsHSP90 Heat-Shock ProteinsHumansPatch-Clamp TechniquesPhenylalanineProtein FoldingProtein TransportTyrosineActivating Transcription Factor 6ATF6 protein, humanBerberineCalnexinCalreticulindihydroberberineEther-A-Go-Go Potassium ChannelsHSP90 Heat-Shock ProteinsPhenylalanineTyrosine

Identifiers

PMID28763460
PMCPMC5538702
OpenAlexW2741058732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.